Cargando…

Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer

BACKGROUND: Non-melanoma skin cancer (NMSC) is the most common malignancy in humans. Targeted therapy with monoclonal antibody cetuximab is an option in case of advanced tumor or metastasis. AIM: We present and update of the use of cetuximab in NMSC searching PUBMED 2011-2017. METHODS: The monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales: Wollina, Uwe, Tchernev, Georgi, Lotti, Torello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Republic of Macedonia 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816291/
https://www.ncbi.nlm.nih.gov/pubmed/29484016
http://dx.doi.org/10.3889/oamjms.2018.022
_version_ 1783300641199751168
author Wollina, Uwe
Tchernev, Georgi
Lotti, Torello
author_facet Wollina, Uwe
Tchernev, Georgi
Lotti, Torello
author_sort Wollina, Uwe
collection PubMed
description BACKGROUND: Non-melanoma skin cancer (NMSC) is the most common malignancy in humans. Targeted therapy with monoclonal antibody cetuximab is an option in case of advanced tumor or metastasis. AIM: We present and update of the use of cetuximab in NMSC searching PUBMED 2011-2017. METHODS: The monoclonal antibody cetuximab against epidermal growth factor receptor (EGFR) has been investigated for its use in NMSC during the years 2011 to 2017 by a PUBMED research using the following items: “Non-melanoma skin cancer AND cetuximab,” “cutaneous squamous cell carcinoma AND cetuximab,” and “basal cell carcinoma AND cetuximab”, and “cetuximab AND skin toxicity”. Available data were analyzed including case reports. RESULTS: Current evidence of cetuximab efficacy in NMSC was mainly obtained in cutaneous SCC and to a lesser extend in BCC. Response rates vary for neoadjuvant, adjuvant, mono- and combined therapy with cetuximab. Management of cutaneous toxicities is necessary. Guidelines are available. CONCLUSIONS: Cetuximab is an option for recurrent or advanced NMSC of the skin. It seems to be justified particularly in very high-risk tumors. There is a need for phase III trials.
format Online
Article
Text
id pubmed-5816291
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Republic of Macedonia
record_format MEDLINE/PubMed
spelling pubmed-58162912018-02-26 Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer Wollina, Uwe Tchernev, Georgi Lotti, Torello Open Access Maced J Med Sci Review Article BACKGROUND: Non-melanoma skin cancer (NMSC) is the most common malignancy in humans. Targeted therapy with monoclonal antibody cetuximab is an option in case of advanced tumor or metastasis. AIM: We present and update of the use of cetuximab in NMSC searching PUBMED 2011-2017. METHODS: The monoclonal antibody cetuximab against epidermal growth factor receptor (EGFR) has been investigated for its use in NMSC during the years 2011 to 2017 by a PUBMED research using the following items: “Non-melanoma skin cancer AND cetuximab,” “cutaneous squamous cell carcinoma AND cetuximab,” and “basal cell carcinoma AND cetuximab”, and “cetuximab AND skin toxicity”. Available data were analyzed including case reports. RESULTS: Current evidence of cetuximab efficacy in NMSC was mainly obtained in cutaneous SCC and to a lesser extend in BCC. Response rates vary for neoadjuvant, adjuvant, mono- and combined therapy with cetuximab. Management of cutaneous toxicities is necessary. Guidelines are available. CONCLUSIONS: Cetuximab is an option for recurrent or advanced NMSC of the skin. It seems to be justified particularly in very high-risk tumors. There is a need for phase III trials. Republic of Macedonia 2017-12-31 /pmc/articles/PMC5816291/ /pubmed/29484016 http://dx.doi.org/10.3889/oamjms.2018.022 Text en Copyright: © 2018 Uwe Wollina, Georgi Tchernev, Torello Lotti. http://creativecommons.org/licenses/CC BY-NC/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
spellingShingle Review Article
Wollina, Uwe
Tchernev, Georgi
Lotti, Torello
Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer
title Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer
title_full Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer
title_fullStr Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer
title_full_unstemmed Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer
title_short Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer
title_sort chimeric monoclonal antibody cetuximab targeting epidermal growth factor-receptor in advanced non-melanoma skin cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816291/
https://www.ncbi.nlm.nih.gov/pubmed/29484016
http://dx.doi.org/10.3889/oamjms.2018.022
work_keys_str_mv AT wollinauwe chimericmonoclonalantibodycetuximabtargetingepidermalgrowthfactorreceptorinadvancednonmelanomaskincancer
AT tchernevgeorgi chimericmonoclonalantibodycetuximabtargetingepidermalgrowthfactorreceptorinadvancednonmelanomaskincancer
AT lottitorello chimericmonoclonalantibodycetuximabtargetingepidermalgrowthfactorreceptorinadvancednonmelanomaskincancer